The second quarter of 2017 was a fairly quiet period for Sanofi, with no surprises making an appearance in the group's 2Q earnings on July 31. Diabetes remains a tough arena for the pharma company, particularly in the US, but its new biologic Dupixent (dupilumab) has performed well in its first few months on the market.
In the second quarter, sales of Sanofi's insulin glargine products Lantus and follow-on version Toujeo, decreased 13.5% to €1.4bn. Individually, Lantus sales were €1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?